We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+24.15%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$185M
Cap. Flow
+$75.5M
Cap. Flow %
5.81%
Top 10 Hldgs %
78.61%
Holding
39
New
8
Increased
5
Reduced
3
Closed
4
Avg Time Held
5.4 quarters
Top 10 Avg Time Held
5 quarters
Top 20 Avg Time Held
6 quarters

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$54.6M
2
STRO icon
Sutro Biopharma
STRO
+$16.6M
3
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
+$15.7M
4
EPZM
Epizyme, Inc
EPZM
+$9.02M
5
MTEM icon
Molecular Templates, Inc.
MTEM
+$8.29M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$34.4M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$13.1M
3
CDTX icon
Cidara Therapeutics
CDTX
+$3.74M
4
VTVT icon
vTv Therapeutics
VTVT
+$1.88M
5
NERV icon
Minerva Neurosciences
NERV
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.28B
$297M 22.84%
10,542,790
– –
2020 Q1
3 quarters
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$566M
$194M 14.91%
5,827,415
– –
2019 Q4
4 quarters
PASG icon
3
Passage Bio
PASG
$11.7M
$128M 9.86%
250,461
– –
2020 Q1
3 quarters
TARS icon
4
Tarsus Pharmaceuticals
TARS
$3.31B
$79.2M 6.1%
+1,917,157
New +$54.6M
2020 Q4
0 quarters
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$5.17B
$62.3M 4.8%
3,566,912
– –
2019 Q3
5 quarters
PCVX icon
6
Vaxcyte
PCVX
$10.4B
$61.4M 4.73%
2,309,554
– –
2020 Q2
2 quarters
IOVA icon
7
Iovance Biotherapeutics
IOVA
$6.57B
$60.9M 4.69%
1,312,999
– –
2016 Q2
18 quarters
KRYS icon
8
Krystal Biotech
KRYS
$9.51B
$53.7M 4.14%
895,000
– –
2018 Q3
9 quarters
TRIL
9
DELISTED
Trillium Therapeutics Inc.
TRIL
$44.9M 3.46%
3,053,107
+264,664
+9% +$3.82M
2020 Q1
3 quarters
TBIO icon
10
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$40.2M 3.1%
2,182,789
– –
2019 Q2
6 quarters
ALPN icon
11
DELISTED
Alpine Immune Sciences Inc
ALPN
$32.4M 2.5%
2,571,450
– –
2017 Q3
13 quarters
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.25B
$31.2M 2.41%
1,405,045
+85,000
+6% +$1.76M
2020 Q1
3 quarters
STRO icon
13
Sutro Biopharma
STRO
$183M
$21.7M 1.67%
+100,142
New +$16.6M
2020 Q4
0 quarters
ANAB icon
14
AnaptysBio
ANAB
$1.36B
$19.3M 1.49%
899,700
-1,416,747
-61% -$34.4M
2017 Q1
15 quarters
COLL icon
15
Collegium Pharmaceutical
COLL
$701M
$18.9M 1.46%
943,666
– –
2015 Q4
20 quarters
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.2M 1.33%
2,494,500
+130,000
+5% +$832K
2020 Q2
2 quarters
FLACU
17
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$15.6M 1.2%
+1,501,000
New +$15.7M
2020 Q4
0 quarters
ADVM icon
18
DELISTED
Adverum Biotechnologies
ADVM
$15.6M 1.2%
143,703
– –
2019 Q4
4 quarters
RGNX icon
19
Regenxbio
RGNX
$479M
$15.5M 1.19%
341,954
+167,754
+96% +$5.86M
2020 Q3
1 quarter
APTX
20
DELISTED
Aptinyx Inc. Common Stock
APTX
$11M 0.85%
3,190,079
– –
2018 Q2
10 quarters
CRDF icon
21
Cardiff Oncology
CRDF
$78.6M
$10.2M 0.79%
568,500
+308,500
+119% +$5.42M
2020 Q3
1 quarter
FRLN
22
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$10M 0.77%
36,667
– –
2020 Q3
1 quarter
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$252M
$9.21M 0.71%
168,000
-360,000
-68% -$13.1M
2020 Q1
3 quarters
GRTS icon
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$8.12M 0.63%
2,061,758
– –
2018 Q3
9 quarters
EPZM
25
DELISTED
Epizyme, Inc
EPZM
$7.94M 0.61%
+731,436
New +$9.02M
2020 Q4
0 quarters
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q4 2020 Portfolio in Review

As of Q4 2020, Frazier Management held 39 positions worth $1.3B, up 17% from $1.11B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Frazier Management deployed $75.5M of net new capital in Q4 2020, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Tarsus Pharmaceuticals: 1,917,157 shares worth $79.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AnaptysBio, an estimated $34.4M trimmed.

  • Frazier Management's largest Q4 2020 buy was Tarsus Pharmaceuticals: 1,917,157 shares worth $79.2M.
  • Frazier Management added most to Regenxbio in Q4 2020, an estimated $5.86M increase.
  • Frazier Management's biggest Q4 2020 reduction was AnaptysBio, cutting an estimated $34.4M.
  • Frazier Management fully exited Cidara Therapeutics in Q4 2020, selling an estimated $3.74M.
  • Frazier Management's ten largest holdings make up 79% of its $1.3B portfolio in Q4 2020.
  • Frazier Management opened 8 new positions and closed 4 in Q4 2020.
  • Frazier Management's portfolio value rose 17% quarter-over-quarter to $1.3B.

Based on Frazier Management's 13F filing for Q4 2020, filed 11 Feb 2021.